GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2024

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Indefinite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	December 31, 2024								December 31, 2023
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(7,749)	$	—	$	2,971	$	10,720	$	(7,050)	$	—	$	3,670
Intangible asset – axicabtagene ciloleucel	7,110		(2,721)		—		4,389		7,110		(2,314)		—		4,796
Intangible asset – Trodelvy	11,730		(3,083)		—		8,647		11,730		(2,002)		—		9,728
Intangible asset – Hepcludex	845		(329)		—		516		845		(243)		—		602
Other	1,474		(940)		1		535		1,414		(827)		1		588
Total finite-lived assets	31,879		(14,822)		1		17,058		31,819		(12,436)		1		19,384
Indefinite-lived assets – IPR&D(1)	2,890		—		—		2,890		7,070		—		—		7,070
Total intangible assets	$	34,769	$	(14,822)	$	1	$	19,948	$	38,889	$	(12,436)	$	1	$	26,454

_______________________________

(1) The Indefinite-lived assets – IPR&D balance as of December 31, 2023 was comprised of $5.9 billion related to sacituzumab govitecan-hziy (“SG”) for non-small cell lung cancer (“NSCLC”) and $1.1 billion related to bulevirtide. See “2024 IPR&D Impairments” below for 2024 activity. The Indefinite-lived assets – IPR&D balance as of December 31, 2024 was comprised of $1.8 billion related to SG for NSCLC and $1.1 billion related to bulevirtide.

Summary of Finite-Lived Intangible Assets

The following table summarizes our Intangible assets, net:


	December 31, 2024								December 31, 2023
(in millions)	Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Foreign Currency Translation Adjustment		Net Carrying Amount
Finite-lived assets:
Intangible asset – sofosbuvir	$	10,720	$	(7,749)	$	—	$	2,971	$	10,720	$	(7,050)	$	—	$	3,670
Intangible asset – axicabtagene ciloleucel	7,110		(2,721)		—		4,389		7,110		(2,314)		—		4,796
Intangible asset – Trodelvy	11,730		(3,083)		—		8,647		11,730		(2,002)		—		9,728
Intangible asset – Hepcludex	845		(329)		—		516		845		(243)		—		602
Other	1,474		(940)		1		535		1,414		(827)		1		588
Total finite-lived assets	31,879		(14,822)		1		17,058		31,819		(12,436)		1		19,384
Indefinite-lived assets – IPR&D(1)	2,890		—		—		2,890		7,070		—		—		7,070
Total intangible assets	$	34,769	$	(14,822)	$	1	$	19,948	$	38,889	$	(12,436)	$	1	$	26,454

_______________________________

Summary of Estimated Future Amortization Expense of Finite-Lived Intangible Assets

The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2024:


(in millions)	Amount
2025	$	2,388
2026	2,379
2027	2,379
2028	2,318
2029	1,790
Thereafter	5,805
Total	$	17,058